Chugai Pharmaceutical (4519 JP): Key Drugs Are Facing Competition; 2022 Target Seems Aggressive
We remain bearish on Chugai Pharmaceutical as its largest selling drugs are facing competition. For 2022, the company is expecting just 1.4% y/y...
489 Views
🇯🇵 JAPAN • Summer Results & Revision Scores - Large Caps
INTRODUCTION - Following on from our previous Insights covering the Market Composite, Sector and Peer Group Aggregate Results and Results &...
656 Views
🇯🇵 Japan • Fortnightly Update - Liquidity Rules
LIQUIDITY RULES - Despite the continuous stream of negative macroeconomic news from Japan and other economies, financial liquidity trends are the...
600 Views
Japan: Fortnightly Update - Thanksgiving Rally
THANKSGIVING RALLY - Japan's equity markets have recovered by 2.4% since 16th November and are now 5% above the October 29th low, but the market...
537 Views
Ono 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Brisk Opdivo domestic (+12% to ¥45.4b) and overseas (estimated royalty of ~¥28b, up 63% y-o-y) sales led robust topline growth of...
504 Views